Knowledge graph · Cancer
Digestive System Adenocarcinoma
subtype
- Identifier
- CI-CAN-00002525
- Entity page
- /cancer/digestive-system-adenocarcinoma ↗
- Edges
- 6,220
- Neighbours
- 15 genes28 drugs10 trials
- Drawn
- 53 of 53 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,147Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Digestive System Adenocarcinoma approved for …APPROVED_FORderived41 of 41show fewer | ||||||||
| ← approved for | Fluorouracilsmall molecule FDA (US) · approved · 2026-02-20 · FAVLYXA is a nucleoside metabolic inhibitor indicated for the treatment of patients with: Adenocarcinoma of the Colon and Rectum | — | approved | Colon Adenocarcinoma | 1 | Regulatory | openfda | graph → |
| ← approved for | ||||||||